Literature DB >> 11377091

Inhibitory actions of luteolin on the growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from ulcer patients.

J G Chung1, T C Hsia, H M Kuo, Y C Li, Y M Lee, S S Lin, C F Hung.   

Abstract

Helicobacter pylori is now recognized as an important cause of type B gastritis, which is strongly associated with gastric and duodenal ulcer disease. H. pylori may be a causative factor in patients with gastric cancer. The growth inhibition and N-acetylation of 2-Aminofluorene (AF) or P-aminobenzoic acid (PABA) by arylamine N-acetyltransferase (NAT) in H. pylori were inhibited by luteolin, a component in herbal medicine. The growth inhibition was based on the changes of optical density (OD) by using a spectrophotometer. The N-acetylation of AF or PABA by NAT from H. pylori were assayed by the amounts of acetylated and non-acetylated AF or PABA in cytosols and intact bacteria of H. pylori by using HPLC. An inhibition of growth on H. pylori demonstrated that luteolin elicited a dose-dependent growth inhibition in the H. pylori cultures. Cytosols and suspensions of H. pylori with or without specific concentrations of luteolin co-treatment showed different percentages of AF or PABA acetylation. The data indicated that there was decreased NAT activity associated with increased levels of luteolin in H. pylori cytosols and suspensions. Using standard steady-state kinetic analysis, it was demonstrated that luteolin was a possible uncompetitive inhibitor to NAT enzyme in H. pylori. This report is the first demonstration to show that luteolin can inhibit H. pylori growth and NAT activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377091     DOI: 10.1016/s0887-2333(01)00015-7

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

Review 1.  Anisi Stellati Fructus, a Significant Traditional Chinese Medicine (TCM) Herb and Its Bioactivity against Gastric Cancer.

Authors:  Maryam Khan; Saba Shamim
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

Review 2.  Structural diversity, functional aspects and future therapeutic applications of human gut microbiome.

Authors:  Soma Ghosh; Sreemanta Pramanik
Journal:  Arch Microbiol       Date:  2021-08-17       Impact factor: 2.552

3.  Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan.

Authors:  Minatsu Kobayashi; Tetsuya Otani; Motoki Iwasaki; Shusuke Natsukawa; Kozo Shaura; Yoichi Koizumi; Yoshio Kasuga; Hiromi Sakamoto; Teruhiko Yoshida; Shoichiro Tsugane
Journal:  Gastric Cancer       Date:  2010-01-05       Impact factor: 7.370

4.  Characterization of AcrD, a resistance-nodulation-cell division-type multidrug efflux pump from the fire blight pathogen Erwinia amylovora.

Authors:  Daniel Pletzer; Helge Weingart
Journal:  BMC Microbiol       Date:  2014-01-21       Impact factor: 3.605

5.  Preparation and evaluation of berberine alginate beads for stomach-specific delivery.

Authors:  Zhen-Hai Zhang; Yong-Shun Sun; Hui Pang; Were L L Munyendo; Hui-Xia Lv; Sheng-Liang Zhu
Journal:  Molecules       Date:  2011-12-14       Impact factor: 4.411

Review 6.  Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.

Authors:  Lorena Avila-Carrasco; Pedro Majano; José Antonio Sánchez-Toméro; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera; Guadalupe González Mateo
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

7.  Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA.

Authors:  Andrés González; Sandra Salillas; Adrián Velázquez-Campoy; Vladimir Espinosa Angarica; María F Fillat; Javier Sancho; Ángel Lanas
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

8.  Preparation and In Vitro-In Vivo Evaluation of Luteolin Loaded Gastroretentive Microsponge for the Eradication of Helicobacter pylori Infections.

Authors:  Mohammed Jafar; Mohammed Salahuddin; Mohd Sajjad Ahmad Khan; Yasir Alshehry; Nazar Radwan Alrwaili; Yazeed Ali Alzahrani; Syed Sarim Imam; Sultan Alshehri
Journal:  Pharmaceutics       Date:  2021-12-06       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.